INVESTIGATOR’S AGREEMENT
I have read the attached protocol titled: A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (ZUMA-1) dated 11 Feb 2019 and agree to abide by all provisions set forth therein. I agree to comply with the International Conference on Harmonisation Tripartite Guideline on Good Clinical Practice and applicable national or regional regulations and guidelines. I agree and will ensure that financial disclosure statements will be completed by:  Me (including, if applicable, my spouse, legal partner and dependent children)  Sub-Investigators (including, if applicable their spouse, legal partner and dependent children) at the start of the study and for up to one year after the study is completed. I agree to ensure that the confidential information contained in this document will not be used for any purpose other than the conduct of the clinical investigation without prior written consent from Kite Pharma Inc.